Minerva Neurosciences Inc. [NASDAQ: NERV] price surged by 27.31 percent to reach at $0.74. The company report on January 20, 2021 that SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Minerva Neurosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2021 – NERV.
New York, New York–(Newsfile Corp. – January 19, 2021) – The following statement is being issued by Levi & Korsinsky, LLP:.
To: All persons or entities who purchased or otherwise acquired securities of Minerva Neurosciences, Inc. (“Minerva Neurosciences”) (NASDAQ: NERV) between May 15, 2017 and November 30, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:.
A sum of 11209011 shares traded at recent session while its average daily volume was at 642.77K shares. Minerva Neurosciences Inc. shares reached a high of $3.75 and dropped to a low of $3.26 until finishing in the latest session at $3.45.
Guru’s Opinion on Minerva Neurosciences Inc. [NERV]:
H.C. Wainwright have made an estimate for Minerva Neurosciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 08, 2020. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on May 14, 2020, representing the official price target for Minerva Neurosciences Inc. stock. Previously, the target price had yet another raise to $17, while Chardan Capital Markets analysts kept a Buy rating on NERV stock.
The Average True Range (ATR) for Minerva Neurosciences Inc. is set at 0.18, with the Price to Sales ratio for NERV stock in the period of the last 12 months amounting to 3.55. The Price to Book ratio for the last quarter was 2.50.
NERV Stock Performance Analysis:
Minerva Neurosciences Inc. [NERV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 34.77. With this latest performance, NERV shares gained by 31.68% in over the last four-week period, additionally sinking by -6.25% over the last 6 months – not to mention a drop of -58.73% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NERV stock in for the last two-week period is set at 75.53, with the RSI for the last a single of trading hit 87.07, and the three-weeks RSI is set at 66.73 for Minerva Neurosciences Inc. [NERV]. The present Moving Average for the last 50 days of trading for this stock 2.96, while it was recorded at 2.83 for the last single week of trading, and 4.49 for the last 200 days.
Insight into Minerva Neurosciences Inc. Fundamentals:
Return on Total Capital for NERV is now -96.11, given the latest momentum, and Return on Invested Capital for the company is -122.18. Return on Equity for this stock declined to -122.30, with Return on Assets sitting at -64.37. When it comes to the capital structure of this company, Minerva Neurosciences Inc. [NERV] has a Total Debt to Total Equity ratio set at 1.02. Additionally, NERV Total Debt to Total Capital is recorded at 1.01, with Total Debt to Total Assets ending up at 0.36. Long-Term Debt to Equity for the company is recorded at 0.40, with the Long-Term Debt to Total Capital now at 0.40.
Reflecting on the efficiency of the workforce at the company, Minerva Neurosciences Inc. [NERV] managed to generate an average of -$5,552,576 per employee.Minerva Neurosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.50 and a Current Ratio set at 6.50.
NERV Stock EPS
With the latest financial reports released by the company, Minerva Neurosciences Inc. posted -0.77/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -102.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NERV.
Minerva Neurosciences Inc. [NERV] Insider Position Details
There are presently around $106 million, or 70.20% of NERV stock, in the hands of institutional investors. The top three institutional holders of NERV stocks are: FEDERATED HERMES, INC. with ownership of 9,610,200, which is approximately 0% of the company’s market cap and around 0.80% of the total institutional ownership; VANGUARD GROUP INC, holding 4,059,409 shares of the stock with an approximate value of $14.01 million in NERV stocks shares; and BLACKROCK INC., currently with $7.25 million in NERV stock with ownership of nearly -4.99% of the company’s market capitalization.
Positions in Minerva Neurosciences Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 27 institutional holders increased their position in Minerva Neurosciences Inc. [NASDAQ:NERV] by around 4,960,327 shares. Additionally, 44 investors decreased positions by around 2,981,651 shares, while 19 investors held positions by with 22,849,472 shares. The mentioned changes placed institutional holdings at 30,791,450 shares, according to the latest SEC report filing. NERV stock had 10 new institutional investments in for a total of 1,813,703 shares, while 14 institutional investors sold positions of 378,812 shares during the same period.